

## Induced pluripotent stem cell (iPSC) clones for Alzheimer's Disease (AD)

### Business Opportunity

AD-specific iPSC clones derived from both sporadic and familial patient's skin express the downstream disease-specific metabolic pathways and provide an excellent tool for disease modelling drug discovery including drug toxicity for AD for which there is no effective cure available.

### The Market

The screening of drug candidates for toxicity is a major cause of attrition in drug development that leads to high costs and reduced number of effective clinical candidates. There is a need for early stage screening of toxic candidates for cost effective development of novel therapeutic agents.

### The Technology

Several disease-specific iPSC clones derived from both the sporadic and familial cases of AD have been fully characterised and are ready for distribution for research and development purposes under licence. A model developed for early detection of AD based on our transcriptomic and proteomic expression

analyses will serve as a platform to the pharmaceutical industry for drug discovery and drug toxicity for AD.


*There is no cellular model available in the market for an early detection of Alzheimer's disease.* With the emergence of small molecule and protein therapeutic discovery, these disease-specific iPSCs can be used for small molecule candidates for treating diseases. In addition to discovering new therapeutics, iPSCs cellular disease models can be used to systematically perturb cells in vitro in order to elucidate mechanisms of disease.

### The Team

The team is composed of the 2010 Scientist of the Year in Biomedical Sciences, Prof Perminder Sachdev, and the 2007 Eureka Prize Finalist A/Prof Kuldip Sidhu, Director of the Stem cell Laboratory at UNSW.

### Investment Opportunity

New South Innovations Pty Ltd is looking to partner with companies interested in commercializing these unique cell lines.



**AD-specific iPSC clone differentiated to neuronal cells**

Further Information: Ref [10\_2468]

Dr Alfredo Martinez-Coll | Commercialisation Manager- Faculty of Medicine

T: +61 2 9385 4679; M: +61 404 014 686

E: a.martinez-coll@nsinnovations.com.au